Published in Drug Metab Dispos on November 04, 2005
Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs (2013) 1.49
Interaction of the mitotic kinesin Eg5 inhibitor monastrol with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol (2005) 0.94
Identification of Small Molecule Inhibitors of Clostridium perfringens ε-Toxin Cytotoxicity Using a Cell-Based High-Throughput Screen. Toxins (Basel) (2010) 0.88
In vitro metabolism of the opioid tilidine and interaction of tilidine and nortilidine with CYP3A4, CYP2C19, and CYP2D6. Naunyn Schmiedebergs Arch Pharmacol (2008) 0.87
Determining P-glycoprotein-drug interactions: evaluation of reconstituted P-glycoprotein in a liposomal system and LLC-MDR1 polarized cell monolayers. J Pharmacol Toxicol Methods (2012) 0.79
Interaction potential of the multitargeted receptor tyrosine kinase inhibitor dovitinib with drug transporters and drug metabolising enzymes assessed in vitro. Pharmaceutics (2014) 0.77
Venetoclax (ABT-199) Might Act as a Perpetrator in Pharmacokinetic Drug-Drug Interactions. Pharmaceutics (2016) 0.76
Use of different parameters and equations for calculation of IC₅₀ values in efflux assays: potential sources of variability in IC₅₀ determination. AAPS J (2013) 0.75
Pharmacokinetic and pharmaceutic interaction between digoxin and Cremophor RH40. Clin Pharmacol Ther (2003) 1.78
Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem Pharmacol (2005) 1.52
Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther (2003) 1.39
Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J Antimicrob Chemother (2007) 1.27
Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem Pharmacol (2007) 1.26
Assessing reported adherence to pharmacological treatment recommendations. Translation and evaluation of the Medication Adherence Report Scale (MARS) in Germany. J Eval Clin Pract (2010) 1.16
Successful strategy to improve the specificity of electronic statin-drug interaction alerts. Eur J Clin Pharmacol (2009) 1.14
Pilot study to assess the influence of an enhanced medication plan on patient knowledge at hospital discharge. Eur J Clin Pharmacol (2014) 1.10
Localization of the human breast cancer resistance protein (BCRP/ABCG2) in lipid rafts/caveolae and modulation of its activity by cholesterol in vitro. J Pharmacol Exp Ther (2007) 1.09
Patients' beliefs about medicines in a primary care setting in Germany. J Eval Clin Pract (2010) 1.06
Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors. Drug Metab Dispos (2006) 1.06
Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients. J Antimicrob Chemother (2011) 1.04
Involvement of drug transporters in the synergistic action of FOLFOX combination chemotherapy. Biochem Pharmacol (2009) 1.02
Frequency of the SLCO1B1 388A>G and the 521T>C polymorphism in Tanzania genotyped by a new LightCycler®-based method. Eur J Clin Pharmacol (2011) 1.01
Potential of novel antiretrovirals to modulate expression and function of drug transporters in vitro. J Antimicrob Chemother (2011) 0.99
Modulation of cellular cholesterol alters P-glycoprotein activity in multidrug-resistant cells. Mol Pharmacol (2004) 0.99
Induction of multiple drug transporters by efavirenz. J Pharmacol Sci (2009) 0.93
Prevention of intravenous drug incompatibilities in an intensive care unit. Am J Health Syst Pharm (2008) 0.92
Pharmacokinetics of linezolid in septic patients with and without extended dialysis. Eur J Clin Pharmacol (2009) 0.92
Impact of drug transporters on cellular resistance towards saquinavir and darunavir. J Antimicrob Chemother (2010) 0.91
Potential of the novel antiretroviral drug rilpivirine to modulate the expression and function of drug transporters and drug-metabolising enzymes in vitro. Int J Antimicrob Agents (2013) 0.90
Interaction of antiepileptic drugs with human P-glycoprotein in vitro. J Pharmacol Exp Ther (2003) 0.89
In vitro metabolism of the opioid tilidine and interaction of tilidine and nortilidine with CYP3A4, CYP2C19, and CYP2D6. Naunyn Schmiedebergs Arch Pharmacol (2008) 0.87
Health care costs in the elderly in Germany: an analysis applying Andersen's behavioral model of health care utilization. BMC Health Serv Res (2014) 0.87
Can a feedback report and training session on medication counseling for general practitioners improve patient satisfaction with information on medicines? Patient Prefer Adherence (2012) 0.87
Interaction profile of macitentan, a new non-selective endothelin-1 receptor antagonist, in vitro. Eur J Pharmacol (2013) 0.86
Impact of ATP-binding cassette transporters on human immunodeficiency virus therapy. Int Rev Cell Mol Biol (2010) 0.86
Effect of the CYP3A inhibitor ketoconazole on the PXR-mediated induction of CYP3A activity. Eur J Clin Pharmacol (2012) 0.85
No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment. Antimicrob Agents Chemother (2010) 0.85
Comparison of the induction of P-glycoprotein activity by nucleotide, nucleoside, and non-nucleoside reverse transcriptase inhibitors. Eur J Pharmacol (2007) 0.85
Knockdown of caveolin-1 decreases activity of breast cancer resistance protein (BCRP/ABCG2) and increases chemotherapeutic sensitivity. Naunyn Schmiedebergs Arch Pharmacol (2010) 0.84
No difference in genotype frequencies of polymorphisms of the nitric oxide pathway between Caucasian normal and high tension glaucoma patients. Mol Vis (2012) 0.84
Interaction of progestins with the human multidrug resistance-associated protein 2 (MRP2). Drug Metab Dispos (2005) 0.83
Lack of evidence for association of high altitude pulmonary edema and polymorphisms of the NO pathway. High Alt Med Biol (2003) 0.83
Reduction of saquinavir exposure by coadministration of loperamide: a two-way pharmacokinetic interaction. Clin Pharmacokinet (2004) 0.83
Differential modulation of the expression of important drug metabolising enzymes and transporters by endothelin-1 receptor antagonists ambrisentan and bosentan in vitro. Eur J Pharmacol (2011) 0.81
Interaction potential of etravirine with drug transporters assessed in vitro. Antimicrob Agents Chemother (2010) 0.81
Significant pharmacokinetic and pharmacodynamic interaction of warfarin with the NO-independent sGC activator HMR1766. J Clin Pharmacol (2007) 0.81
Cellular uptake kinetics of bortezomib in relation to efficacy in myeloma cells and the influence of drug transporters. Cancer Chemother Pharmacol (2014) 0.80
Characteristics of medication schedules used by elderly ambulatory patients. Eur J Clin Pharmacol (2015) 0.80
Daily honey consumption does not change CYP3A activity in humans. J Clin Pharmacol (2010) 0.80
Association of liver stiffness with hepatic expression of pharmacokinetically important genes in alcoholic liver disease. Alcohol Clin Exp Res (2012) 0.79
P-glycoprotein modulation by the designer drugs methylenedioxymethamphetamine, methylenedioxyethylamphetamine and paramethoxyamphetamine. Addict Biol (2003) 0.79
Influence of lipid lowering fibrates on P-glycoprotein activity in vitro. Biochem Pharmacol (2004) 0.79
Influence of sildenafil and tadalafil on the enzyme- and transporter-inducing effects of bosentan and ambrisentan in LS180 cells. Biochem Pharmacol (2012) 0.78
Inappropriate crushing information on ward lists: cytotoxic drugs, capsules, and modified release formulations are gravely neglected. Eur J Clin Pharmacol (2014) 0.78
Evaluation of drug transporters' significance for multidrug resistance in head and neck squamous cell carcinoma. Head Neck (2010) 0.77
Interaction potential of the endothelin-A receptor antagonist atrasentan with drug transporters and drug-metabolising enzymes assessed in vitro. Cancer Chemother Pharmacol (2011) 0.77
Minor role of pregnane-x-receptor for acquired multidrug resistance in head and neck squamous cell carcinoma in vitro. Cancer Chemother Pharmacol (2013) 0.77
Inhibition of the human organic anion transporter 1 by the caffeine metabolite 1-methylxanthine. Biochem Biophys Res Commun (2004) 0.77
Poor solubility limiting significance of in-vitro studies with HIV protease inhibitors. AIDS (2002) 0.77
Rifampicin alters the expression of reference genes used to normalize real-time quantitative RT-PCR data. Naunyn Schmiedebergs Arch Pharmacol (2012) 0.77
Reduced exposure variability of the CYP3A substrate simvastatin by dose individualization to CYP3A activity. J Clin Pharmacol (2013) 0.76
Plasma LDL cholesterol has no impact on P-glycoprotein (MDR1/ABCB1) activity in human peripheral blood mononuclear cells. Naunyn Schmiedebergs Arch Pharmacol (2007) 0.76
Expression and activity of P-glycoprotein (MDR1/ABCB1) in peripheral blood mononuclear cells from patients with anorexia nervosa compared with healthy controls. Int J Eat Disord (2008) 0.76
Drug utilization patterns and reported health status in ethnic German migrants (Aussiedler) in Germany: a cross-sectional study. BMC Public Health (2011) 0.76
Do we prescribe what patients prefer? Pilot study to assess patient preferences for medication regimen characteristics. Patient Prefer Adherence (2012) 0.75
One-year follow-up on procedure to prevent i.v. drug incompatibilities in an intensive care unit. Am J Health Syst Pharm (2009) 0.75
Prolyl Hydroxylase Inhibition Enhances Liver Regeneration Without Induction of Tumor Growth. Ann Surg (2017) 0.75
Rapid and reliable genotyping of the C181T polymorphism in the bradykinin B2 receptor gene. Clin Chem Lab Med (2003) 0.75
Effects of adrenolytic mitotane on drug elimination pathways assessed in vitro. Endocrine (2014) 0.75
[Does implementation of benchmarking in quality circles improve the quality of care of patients with asthma and reduce drug interaction?]. Z Evid Fortbild Qual Gesundhwes (2011) 0.75
Development and evaluation of an algorithm to facilitate drug prescription for inpatients with feeding tubes. Eur J Clin Pharmacol (2015) 0.75
[Off-label use in long-term anticoagulation after liver transplantation due to phenprocoumon-induced hepatic failure]. Med Klin (Munich) (2005) 0.75
The effect of induction of CYP3A4 by St John's wort on ambrisentan plasma pharmacokinetics in volunteers of known CYP2C19 genotype. Basic Clin Pharmacol Toxicol (2014) 0.75
[Off label use in long-term anticoagulation after liver transplantation due to phenprocoumon-induced hepatic failure]. Med Monatsschr Pharm (2006) 0.75